Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $25.26, for a total transaction of $126,300.00. Following the sale, the director now directly owns 92,467 shares in the company, valued at $2,335,716.42. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
NASDAQ:LNTH opened at $24.15 on Friday. The company has a debt-to-equity ratio of 3.71, a quick ratio of 3.08 and a current ratio of 3.70. Lantheus Holdings Inc has a 52 week low of $12.59 and a 52 week high of $26.30. The firm has a market capitalization of $930.93 million, a PE ratio of 25.16, a PEG ratio of 1.74 and a beta of 1.59.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, February 19th. The medical equipment provider reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.09. Lantheus had a net margin of 11.80% and a return on equity of 73.07%. The company had revenue of $86.27 million for the quarter, compared to analyst estimates of $83.93 million. During the same period in the prior year, the firm posted $2.47 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Equities research analysts forecast that Lantheus Holdings Inc will post 1.15 earnings per share for the current year.
A number of research firms have weighed in on LNTH. BidaskClub lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Thursday. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Tuesday, April 16th. TheStreet raised shares of Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. Finally, ValuEngine raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Lantheus has an average rating of “Buy” and a consensus price target of $23.33.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/lantheus-holdings-inc-lnth-director-sells-126300-00-in-stock.html.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Featured Article: What is a Swap?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.